Drugs · acquisition-cost intelligence
Lucemyra
Lofexidine· ingredient lofexidine· LOFEXIDINE HYDROCHLORIDE .18 mg/1; LOFEXIDINE HYDROCHLORIDE .2 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$10.30
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 8 weeks.
2025-11-192026-06-03
Medicare Part D coverage · CY2026
On 39 plan formularies · typical tier 5
Prior auth 46% · Step therapy 0% · Quantity limit 62% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.